![Sophie Pierrin-Lépinard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sophie Pierrin-Lépinard
Direktor/Vorstandsmitglied bei ScreenCell SA
Aktive Positionen von Sophie Pierrin-Lépinard
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ScreenCell SA
![]() ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Direktor/Vorstandsmitglied | 17.02.2011 | - |
BNP Paribas Développement SA
![]() BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Private Equity Investor | 01.12.2017 | - |
Karriereverlauf von Sophie Pierrin-Lépinard
Ehemalige bekannte Positionen von Sophie Pierrin-Lépinard
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Banexi Ventures Partners SA
![]() Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Direktor/Vorstandsmitglied | 25.03.2009 | 16.11.2016 |
Mitglied des Investmentausschusses | 01.01.1999 | 25.03.2009 | |
Private Equity Investor | 01.01.1999 | 16.11.2016 | |
Apoxis SA
![]() Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - | 01.08.2007 |
Antabio SAS
![]() Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Direktor/Vorstandsmitglied | - | - |
Kreaxi SASU
![]() Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Private Equity Investor | 01.11.2016 | - |
SYMETIS SA | Direktor/Vorstandsmitglied | 11.10.2010 | - |
Ausbildung von Sophie Pierrin-Lépinard
Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
ESCP Europe Campus Paris | Graduate Degree |
Statistik
International
Frankreich | 8 |
Schweiz | 3 |
Operativ
Director/Board Member | 4 |
Private Equity Investor | 3 |
Investment Committee Member | 1 |
Sektoral
Finance | 4 |
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
Banexi Ventures Partners SA
![]() Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Finance |
Apoxis SA
![]() Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Symetis SA
![]() Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
ScreenCell SA
![]() ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Commercial Services |
Kreaxi SASU
![]() Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Finance |
BNP Paribas Développement SA
![]() BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Finance |
Antabio SAS
![]() Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Health Technology |
- Börse
- Insiders
- Sophie Pierrin-Lépinard
- Erfahrung